Financial HealthCertainty around Xifaxan is critical to the financial health of BHC, and the current legal situation could jeopardize or delay BLCO share distribution.
Generic CompetitionKey factors contributing to that uncertainty include the possibility that Norwich or another generics manufacturer could file a new ANDA claiming only the IBS indication.
LitigationUncertainty persists as additional litigation with Amneal is already underway, and it is not impossible that Norwich tries again.